Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis largely owing to inefficient diagnosis and tenacious drug resistance. Activation of pancreatic stellate cells (PSCs) and consequent development of dense stroma are prominent features accounting for this aggressive biology^1,2. The reciprocal interplay between PSCs and pancreatic cancer cells (PCCs) not only enhances tumour progression and metastasis but also sustains their own activation, facilitating a vicious cycle to exacerbate tumorigenesis and drug resistance^3-7. Furthermore, PSC activation occurs very early during PDAC tumorigenesis^8-10, and activated PSCs comprise a substantial fraction of the tumour mass, providing a rich source of readily detectable factors. Therefore, we hypothesized th

SUBMITTER: Shi Y 

PROVIDER: S-EPMC6565370 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature